J9213 HCPCS code: Injection, interferon, alfa-2a, recombinant, 3 million units
J9213 is the HCPCS Level II code for injection, interferon, alfa-2a, recombinant, 3 million units. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 12 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 1993-01-01 |
| Last action effective | 2024-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 12 | Prescribing Information |
| practitioner claims | 12 | Prescribing Information |
What changed for J9213
- 1993-01-01: J9213 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9213?
J9213 is the HCPCS Level II code for injection, interferon, alfa-2a, recombinant, 3 million units. Short descriptor: "Interferon alfa-2a inj".
Does Medicare cover J9213?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
How many units of J9213 can be billed per day?
12 on outpatient hospital claims; 12 on practitioner claims (NCCI medically unlikely edits).
Related J92 codes
- J9200 — Injection, floxuridine, 500 mg
- J9201 — Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
- J9202 — Goserelin acetate implant, per 3.6 mg
- J9203 — Injection, gemtuzumab ozogamicin, 0.1 mg
- J9204 — Injection, mogamulizumab-kpkc, 1 mg
- J9205 — Injection, irinotecan liposome, 1 mg
- J9206 — Injection, irinotecan, 20 mg
- J9207 — Injection, ixabepilone, 1 mg
- J9208 — Injection, ifosfamide, 1 gram
- J9209 — Injection, mesna, 200 mg
- J9210 — Injection, emapalumab-lzsg, 1 mg
- J9211 — Injection, idarubicin hydrochloride, 5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9213
- Watch J9213 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9213
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.